相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- BioMarin Pharmaceutical Inc. has entered a definitive agreement to acquire Alesta Therapeutics, gaining the clinical-stage asset ALE1 for a $275 million upfront payment plus up to $215 million in milestone payments. - ALE1 is an orally active small molecule with the potential to be the first oral therapy for hypophosphatasia (HPP), a rare genetic bone disease caused by ALPL gene mutations. - ALE1 targets inorganic pyrophosphate (PPi), the central disease metabolite, and is currently in a Phase 1/2a trial assessing safety, tolerability, and pharmacokinetics/pharmacodynamics. - The transaction is expected to close this quarter, with Alesta spinning out all non-ALE1 assets and transferring its employees to a new entity prior to close.
- BioMarin Pharmaceutical will acquire privately held Alesta Therapeutics for $275 million up front, with up to $215 million more in development and regulatory milestones. - Alesta's lead candidate ALE1 is in a Phase 1/2 trial for hypophosphatasia, a genetic disease affecting bone mineralization that can cause fractures, tooth loss, and muscle weakness. - ALE1 acts on a novel target that lowers inorganic pyrophosphate, a metabolite central to hypophosphatasia, and could reach BioMarin's largest addressable patient population. - The deal, BioMarin's third acquisition in two years, is expected to close by the end of September and will be funded with cash on hand.
- AstraZeneca's asfotase alfa (STRENSIQ) posted Q1 2026 revenue of USD 517 million, a 43% increase at constant exchange rates, reflecting sustained global demand as the only approved disease-modifying therapy for hypophosphatasia. - Efzimfotase alfa (ALXN1850) demonstrated positive Phase III results and has received both Fast Track and Orphan Drug Designation from the FDA, positioning it as a key next-generation enzyme replacement therapy. - Alesta Therapeutics' oral small-molecule therapy ALE1 advanced into clinical development with Phase I/IIa data expected in H2 2026, backed by a €65 million Series A financing. - Increasing diagnostic awareness and genetic testing for ALPL mutations are expanding the treatable patient pool, particularly among adult and milder phenotypes that remain significantly underdiagnosed.
